Jupiter Neurosciences EBITDA 2023-2025 | JUNS

Jupiter Neurosciences ebitda from 2023 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Jupiter Neurosciences EBITDA 2023-2025 | JUNS

Jupiter Neurosciences ebitda from 2023 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$71.1B
Zoetis (ZTS)$68.9B
Takeda Pharmaceutical (TAK)$47.3B
Daiichi Sankyo, - (DSNKY)$46B
BeOne Medicines - (ONC)$32.9B
Sandoz Group AG (SDZNY)$27.7B
Summit Therapeutics (SMMT)$18.4B
Merck (MKKGY)$16.3B
Shionogi (SGIOY)$14.7B
United Therapeutics (UTHR)$13.8B
Neurocrine Biosciences (NBIX)$13.7B
Orion OYJ (ORINY)$11.2B
IPSEN (IPSEY)$11.2B
Madrigal Pharmaceuticals (MDGL)$9.4B
Eisai (ESAIY)$9.1B
Corcept Therapeutics (CORT)$7.3B
Ionis Pharmaceuticals (IONS)$6.8B
Stevanato Group S.p.A (STVN)$6.8B
Grifols, S.A (GRFS)$6.7B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.9B
Crinetics Pharmaceuticals (CRNX)$2.9B
Hypermarcas (HYPMY)$2.8B
Procaps Group, S.A (PROCF)$2.8B
NewAmsterdam Pharma (NAMS)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$2.1B